EVLO (Evelo Biosciences) Retained Earnings: $-588.03 Mil (As of Sep. 2023)


What is Evelo Biosciences Retained Earnings?

Evelo Biosciences EVLO Retained Earnings is $-588.03 Mil as of Sep. 2023.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Evelo Biosciences's retained earnings for the quarter that ended in Sep. 2023 was $-588.03 Mil.

Evelo Biosciences's quarterly retained earnings declined from Mar. 2023 ($-554.56 Mil) to Jun. 2023 ($-575.67 Mil) and declined from Jun. 2023 ($-575.67 Mil) to Sep. 2023 ($-588.03 Mil).

Evelo Biosciences's annual retained earnings declined from Dec. 2020 ($-292.52 Mil) to Dec. 2021 ($-414.70 Mil) and declined from Dec. 2021 ($-414.70 Mil) to Dec. 2022 ($-529.22 Mil).

Evelo Biosciences  (OTCPK:EVLO) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Evelo Biosciences Retained Earnings Historical Data

* Premium members only.

The historical data trend for Evelo Biosciences's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evelo Biosciences Retained Earnings Chart

Evelo Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Retained Earnings
Get a 7-Day Free Trial -113.38 -198.85 -292.52 -414.70 -529.22

Evelo Biosciences Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -505.68 -529.22 -554.56 -575.67 -588.03

Evelo Biosciences Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of $-588.03 Mil mean?
Evelo Biosciences (EVLO) has a Retained Earnings of $-588.03 Mil as of Sep. 2023. Retained earnings is the amount of net income not issued to shareholders. View historical data on Evelo Biosciences and its competitors.
Is Evelo Biosciences' Retained Earnings too high?
Evelo Biosciences' current Retained Earnings is $-588.03 Mil.
How does Evelo Biosciences' Retained Earnings compare to IMNN and EDSA?
Evelo Biosciences' Retained Earnings of $-588.03 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Biotechnology company?
A good Retained Earnings depends on the Biotechnology industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Evelo Biosciences and its competitors. Evelo Biosciences's current Retained Earnings is $-588.03 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evelo Biosciences stock overvalued right now?
Evelo Biosciences (EVLO) has a current Retained Earnings of $-588.03 Mil. The current Retained Earnings is $-588.03 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Evelo Biosciences (EVLO), the current Retained Earnings is $-588.03 Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Evelo Biosciences Business Description

Address 620 Memorial Drive, Cambridge, MA, USA, 02139
Evelo Biosciences Inc is a clinical-stage biotechnology company focused on discovering and developing a new class of oral medicines that act on immune cells in the small intestine with systemic effects. The company is developing EDP1815 as a treatment in psoriasis and atopic dermatitis and EDP2939 in psoriasis.